If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-13. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
==== Addictiveness and dependence ==== Frequent use of GHB or GBL, even when taken long-term and in moderate doses, does not appear to cause significant physical dependency in the majority of its users. In many people, quitting or temporarily abstaining from use of the drugs is achieved with minimal or no difficulty. However, when consumed in excessive amounts with a high frequency of dosing, physical and psychological dependence can develop. Management of GBL dependence involves considering the person's age, comorbidity and the pharmacological pathways of GBL. GHB and GBL users can adopt a '24/7' dosing regime. This is where the user has become tolerant to the effects of the drug, increasing the dosage and frequency of dosage simply to avoid withdrawal symptoms. For those users who do report withdrawal symptoms upon quitting the use of GHB or GBL, symptoms seem to depend on the dosage and the length of time the drug was used. Light to moderate users often experience insomnia and sleep-related problems, whereas heavy, prolonged use can cause severe withdrawal symptoms similar to Benzodiazepine withdrawal syndrome (BWS).
Amid decolonisation and the Wind of Change, the Federation failed to become a Commonwealth realm and collapsed in 1963. Two years later, following prolonged dispute with Britain over the terms for full sovereignty, the mostly white government in Southern Rhodesia (or Rhodesia, following Northern Rhodesia's independence as Zambia) issued a Unilateral Declaration of Independence (UDI). The Rhodesian government, which had in it World War II veterans including the Prime Minister Ian Smith, attempted to emphasise Rhodesians' prior war record on Britain's behalf by declaring independence on Armistice Day, 11 November, at 11:00 local time. As part of its subsequent isolation of Rhodesia, the UK government banned the post-UDI authorities from taking part in the annual Armistice Day service at the Cenotaph in London. Smith's government organised its own Rhodesian wreath-laying ceremony there. Veterans of World War II and Malaya held many key positions in the Rhodesian Security Forces during the Bush War of the 1970s. After the country's reconstitution and recognised independence as Zimbabwe in 1980, Robert Mugabe's administration pulled down many monuments and plaques making reference to the dead of the First and Second World Wars, perceiving them as reminders of white minority rule and colonialism that went against what the modern state stood for. This view was partly rooted in the association of these memorials with those commemorating the British South Africa Company's dead of the Matabele Wars, as well as those memorialising Rhodesian servicemen killed during the Bush War.
Pickens reprised the role in two episodes of the 10th season revival and currently (2019) appears on a recurring basis on The Conners. Mr. Parkin (Stan Freberg) – A highly qualified man who is frequently unemployed due to various incidents with the Conners. Scott (Fred Willard) – A probate attorney who marries Leon. Stinky (Matthew Fishman) – Roseanne's youngest child in an alternate reality, in the place of Jerry. Ziggy (Jay O. Sanders) – An old friend of the Conners. Roseanne reveals that his real name is Norbert, then asks, "does your mom still call you Norbie?" Ziggy helps Dan open Lanford Custom Cycle, then disappears. Jimmy Gartner (Danny Masterson) – Darlene's boyfriend, for whom she breaks up with David. In the 16th episode of season 7, Darlene confesses to Jackie that he broke up with her because he could not get close to her. Ronnie (Joan Collins) – Roseanne's rich cousin who persuades Darlene to get her GED and apply to art school.
Sources: en.wikipedia.org
From 1946 through 1993, thirteen countries used ocean disposal or ocean dumping as a method to dispose of nuclear/radioactive waste with an approximation of 200,000 tons sourcing mainly from the medical, research and nuclear industry. Ocean floor disposal of radioactive waste has been suggested by the finding that deep waters in the North Atlantic Ocean do not present an exchange with shallow waters for about 140 years based on oxygen content data recorded over a period of 25 years. They include burial beneath a stable abyssal plain, burial in a subduction zone that would slowly carry the waste downward into the Earth's mantle, and burial beneath a remote natural or human-made island. While these approaches all have merit and would facilitate an international solution to the problem of disposal of radioactive waste, they would require an amendment of the Law of the Sea. Nuclear submarines have been lost and these vessels reactors must also be counted in the amount of radioactive waste deposited at sea. Article 1 (Definitions), 7., of the 1996 Protocol to the Convention on the Prevention of Marine Pollution by Dumping of Wastes and Other Matter, (the London Dumping Convention) states:
Humulin R (REGULAR human insulin injection [rDNA origin]) is a short-acting insulin that has a relatively short duration of activity as compared with other insulins. Humulin R Regular U-500 (Concentrated) insulin human injection, USP (rDNA Origin) is a stronger concentration (500 units/mL) of Humulin R. Humulin 70/30 (70% human insulin isophane suspension, 30% human insulin injection [rDNA origin]) is a mixture insulin. It is an intermediate-acting insulin combined with the onset of action of Humulin Humulin 50/50 (50% human insulin isophane suspension, 50% human insulin injection [rDNA origin]) is a mixture insulin. It is an intermediate-acting insulin combined with the onset of action of Humulin R. In UK these include:
Most corps have one. In general, western provinces with large non-Han population have more than those in China's interior. Corps are further subdivided at lower administrative levels. Regimental-level detachments (Chinese: 支队; pinyin: zhīduì) are found in provinces, prefectures, and specifically designated cities. Battalions (Chinese: 大队; pinyin: dadui) are located in districts of the important cities and counties. Companies (Chinese: 中队; pinyin: zhōngduì) are found in counties. All corps have subordinate elementary command colleges.
Sources: en.wikipedia.org
In 1998, a fraudulent paper by Andrew Wakefield was published in The Lancet presenting apparent evidence of a link between the MMR vaccine, gastrointestinal disease and autism. In this paper, which has since been retracted, Wakefield et al. speculated that food-derived peptides "may exert central-opioid effects, directly or through the formation of ligands with peptidase enzymes required for breakdown of endogenous central-nervous-system opioids, leading to disruption of normal neuroregulation and brain development by endogenous encephalins and endorphins".
The SAF is being developed to respond to a wide range of issues in both conventional and unconventional warfare. The Defence Science and Technology Agency (DSTA) is responsible for procuring resources for the military. The geographic restrictions of Singapore mean that the SAF must plan to fully repulse an attack, as they cannot fall back and re-group. The small size of the population has also affected the way the SAF has been designed, with a small active force and a large number of reserves.
The muscular part of the uvula (Latin: musculus uvulae) shortens and broadens the uvula. This changes the contour of the posterior part of the soft palate. This change in contour allows the soft palate to adapt closely to the posterior pharyngeal wall to help close the nasopharynx during swallowing. Its muscles are controlled by the pharyngeal branch of the vagus nerve.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
Dry powder is typically kept frozen, desiccated, and protected from light. Avoiding moisture exposure and large temperature swings helps slow degradation. Storage recommendations vary by supplier and should be followed for the specific material.